✦ LIBER ✦

Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients

✍ Scribed by Tatiana O. Ajimura; Keyller B. Borges; Aline F. Ferreira; Fabíola A. de Castro; Cristiane M. de Gaitani

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 174 KB
Volume: 32
Category: Article
ISSN: 0173-0835
DOI: 10.1002/elps.201000642

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Successful treatment of chronic myeloid

Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis

✍ Evren Ozdemir; Yener Koc; Emin Kansu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 2 views

Efficacy of imatinib dose escalation in

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

✍ Hagop M. Kantarjian; Richard A. Larson; Francois Guilhot; Stephen G. O'Brien; Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB 👁 1 views

Pharmacokinetics of nilotinib in imatini

Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure

✍ Takashi Onaka; Naoto Takahashi; Masatomo Miura; Akihito Yonezawa; Kazunori Imada 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 425 KB 👁 2 views

Clinical course of thrombocytopenia in p

Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia

✍ Hendrik W. van Deventer; Melissa D. Hall; Robert Z. Orlowski; Beverly S. Mitchel 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Phase 1 study of lonafarnib (SCH 66336)

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

✍ Jorge Cortes; Elias Jabbour; George Q. Daley; Susan O'Brien; Srdan Verstovsek; A 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Abstract ## BACKGROUND. Lonafarnib is an orally bioavailable nonpetidomimetic farnesyl transferase inhibitor with significant activity against BCR‐ABL‐positive cell lines and primary human chronic myeloid leukemia (CML) cells. Lonafarnib can inhibit the proliferation of imatinib‐resistant cells

Phase II study of low-dose decitabine in

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

✍ Yasuhiro Oki; Hagop M. Kantarjian; Vazganush Gharibyan; Dan Jones; Susan O'Brien 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 1 views